PRESS-RELEASE filed Sep 11, 2026 at 09:02 ET
Eli Lilly completed its acquisition of AtaiBeckley, a clinical-stage biopharma developing neuroplastogens for mental health conditions, including its lead candidate BPL-003 for treatment-resistant depression. The deal expands Lilly's neuroscience pipeline into a novel, rapid-acting therapeutic class for a large unmet need, though no financial terms were disclosed and the assets remain early-stage with clinical and regulatory risk. The acquisition is a strategic pipeline addition for a $1T+ mega-cap, making it a modest positive rather than a transformative event for the stock.